Gayatri Phadke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gayatri Phadke has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Anupama Kapadia
4 shared publicationsUttkarsha Bhosale
4 shared publicationsAjeet Singh
Council of Scientific and Industrial Research-National Chemical Laboratory, Chemical Engineering Division, Dr. Homi Bhabha Rd, Pune 411 008, India
2 shared publications- James F. Rusling
Department of Chemistry, University of Connecticut, Storrs, CT 06269, USA
2 shared publications - Riya Thomas
Koc University
2 shared publications Avinash D Ghanate
Council of Scientific and Industrial Research-National Chemical Laboratory, Chemical Engineering Division, Dr. Homi Bhabha Rd, Pune 411 008, India
1 shared publication
Latest Publications
- Open Access
- 16 January 2024
- Published by Front Matter
Need for Consistent and Uniform Guidelines Regarding the Use and Disclosure of AI-generated Scholarly Content
As we witness the ever-evolving landscape of technology, we realize that artificial intelligence (AI) is not just a buzzword anymore; it's a reality that is already leading to transformation in how scholarly research is published and disseminated.
- 16 January 2024
- Published by Front Matter
Open AccessNeed for Consistent and Uniform Guidelines Regarding the Use and Disclosure of AI-generated Scholarly Content
As we witness the ever-evolving landscape of technology, we realize that artificial intelligence (AI) is not just a buzzword anymore; it's a reality that is already leading to transformation in how scholarly research is published and disseminated.
- Open Access
- 16 January 2024
- Published by Front Matter
Need for Consistent and Uniform Guidelines Regarding the Use and Disclosure of AI-generated Scholarly Content
As we witness the ever-evolving landscape of technology, we realize that artificial intelligence (AI) is not just a buzzword anymore; it's a reality that is already leading to transformation in how scholarly research is published and disseminated.
- 16 January 2024
- Published by Front Matter
Open AccessNeed for Consistent and Uniform Guidelines Regarding the Use and Disclosure of AI-generated Scholarly Content
As we witness the ever-evolving landscape of technology, we realize that artificial intelligence (AI) is not just a buzzword anymore; it's a reality that is already leading to transformation in how scholarly research is published and disseminated.
- Open Access
- 4 July 2023
- Published by Front Matter
A Fairer Future for Open Science: Choosing community over commercialization with equitable article processing charges
The open access (OA) movement has undoubtedly revolutionized the accessibility of scholarly research, aiming to make knowledge freely available to all. While many countries have embraced OA publishing with supportive policies, a persistent obstacle remains—article processing charges (APCs). These charges/fees have led to a debate within the academic community, questioning whether they align with the best interests of open science.
- 4 July 2023
- Published by Front Matter
Open AccessA Fairer Future for Open Science: Choosing community over commercialization with equitable article processing charges
The open access (OA) movement has undoubtedly revolutionized the accessibility of scholarly research, aiming to make knowledge freely available to all. While many countries have embraced OA publishing with supportive policies, a persistent obstacle remains—article processing charges (APCs). These charges/fees have led to a debate within the academic community, questioning whether they align with the best interests of open science.
- Open Access
- 4 July 2023
- Published by Front Matter
A Fairer Future for Open Science: Choosing community over commercialization with equitable article processing charges
The open access (OA) movement has undoubtedly revolutionized the accessibility of scholarly research, aiming to make knowledge freely available to all. While many countries have embraced OA publishing with supportive policies, a persistent obstacle remains—article processing charges (APCs). These charges/fees have led to a debate within the academic community, questioning whether they align with the best interests of open science.
- 4 July 2023
- Published by Front Matter
Open AccessA Fairer Future for Open Science: Choosing community over commercialization with equitable article processing charges
The open access (OA) movement has undoubtedly revolutionized the accessibility of scholarly research, aiming to make knowledge freely available to all. While many countries have embraced OA publishing with supportive policies, a persistent obstacle remains—article processing charges (APCs). These charges/fees have led to a debate within the academic community, questioning whether they align with the best interests of open science.
- 1 October 2018
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 143 (22) , 5505-5511
A novel and accurate microfluidic assay of CD62L in bladder cancer serum samples
We report a low-cost, sensitive, bead-based electrochemical immunoarray for soluble L-selectin (or CD62L protein), a potential biomarker for staging bladder cancer. We used a semi-automated modular microfluidic array with online antigen capture on superparamagnetic beads, which were subsequently delivered to a detection chamber housing multiple sensors. The assay was designed to accurately detect CD62L in diluted serum with a limit of detection (LOD) of 0.25 ng mL−1 and a dynamic range of 0.25–100 ng mL−1. The microfluidic array gave significantly better accuracy and higher sensitivity than a standard ELISA kit, which was shown to be subject to significant systematic error at high and low concentration ranges. 31 serum samples from patients with varying grades of bladder cancer and cancer-free controls were analyzed by the immunoarray and ELISA, and the CD62L levels correlated. This work establishes a new accurate assay for determining CD62L levels and highlights the potential of this protein as a biomarker for detecting locoregional progression of bladder cancer.
- 1 October 2018
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 143 (22) , 5505-5511
A novel and accurate microfluidic assay of CD62L in bladder cancer serum samples
We report a low-cost, sensitive, bead-based electrochemical immunoarray for soluble L-selectin (or CD62L protein), a potential biomarker for staging bladder cancer. We used a semi-automated modular microfluidic array with online antigen capture on superparamagnetic beads, which were subsequently delivered to a detection chamber housing multiple sensors. The assay was designed to accurately detect CD62L in diluted serum with a limit of detection (LOD) of 0.25 ng mL−1 and a dynamic range of 0.25–100 ng mL−1. The microfluidic array gave significantly better accuracy and higher sensitivity than a standard ELISA kit, which was shown to be subject to significant systematic error at high and low concentration ranges. 31 serum samples from patients with varying grades of bladder cancer and cancer-free controls were analyzed by the immunoarray and ELISA, and the CD62L levels correlated. This work establishes a new accurate assay for determining CD62L levels and highlights the potential of this protein as a biomarker for detecting locoregional progression of bladder cancer.
- 1 May 2017
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 100 (3) , 640-646
Determination of Triazines and Triazoles in Grapes Using Atmospheric Pressure Matrix-Assisted Laser Desorption/Ionization High-Resolution Mass Spectrometry
A chromatography-free atmospheric pressure matrix-assisted laser desorption/ionization high-resolution mass spectrometry (AP-MALDI HRMS) method is described for the simultaneous and quantitative detection of triazines and triazoles in grapes. The analytes were detected reproducibly with high mass accuracy (mass error within 5 ppm) and further confirmed by collision-induced dissociation fragmentation in tandem MS. The LODs and LOQs for all the analytes were found to be in the nanogram per gram level (15–20 ng/g LOQ). Internal standard–normalized high-resolution accurate mass–extracted (HR-AM) peak intensities of the detected ions were used to generate the concentration response curves. Linearity (with R2 values around 0.99) was obtained for these curves within a concentration range of 20–200 ng/g of the individual analytes. The accuracy and precision of the method were further established using QC samples. Validation and performance comparison of the AP-MALDI HRMS method with an existing standard method using LC with triple quadrupole MS was carried out (evaluating sensitivity, accuracy, precision, and analysis time) using 20 table-grape field samples after QuEChERS extraction.
- 1 May 2017
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 100 (3) , 640-646
Determination of Triazines and Triazoles in Grapes Using Atmospheric Pressure Matrix-Assisted Laser Desorption/Ionization High-Resolution Mass Spectrometry
A chromatography-free atmospheric pressure matrix-assisted laser desorption/ionization high-resolution mass spectrometry (AP-MALDI HRMS) method is described for the simultaneous and quantitative detection of triazines and triazoles in grapes. The analytes were detected reproducibly with high mass accuracy (mass error within 5 ppm) and further confirmed by collision-induced dissociation fragmentation in tandem MS. The LODs and LOQs for all the analytes were found to be in the nanogram per gram level (15–20 ng/g LOQ). Internal standard–normalized high-resolution accurate mass–extracted (HR-AM) peak intensities of the detected ions were used to generate the concentration response curves. Linearity (with R2 values around 0.99) was obtained for these curves within a concentration range of 20–200 ng/g of the individual analytes. The accuracy and precision of the method were further established using QC samples. Validation and performance comparison of the AP-MALDI HRMS method with an existing standard method using LC with triple quadrupole MS was carried out (evaluating sensitivity, accuracy, precision, and analysis time) using 20 table-grape field samples after QuEChERS extraction.
- 5 July 2015
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 407 (23) , 7239-7243
Ultrasensitive microfluidic array for serum pro-inflammatory cytokines and C-reactive protein to assess oral mucositis risk in cancer patients
In addition to disease diagnostics, there is a need for biomarkers to predict severity of cancer therapy side effects such as oral mucositis. Oral mucositis is an inflammatory lesion of oral mucosa caused by high-dose chemotherapy and/or radiation that is especially prevalent during oral cancer treatment. We describe here a semi-automated, modular microfluidic immunoarray optimized for ultrasensitive detection of pro-inflammatory cytokines involved in pathobiology of oral mucositis. Our goal is to methodologically identify risk of mucositis early in oral cancer treatment, before the onset of lesions. Biomarkers include tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), and C-reactive protein (CRP). Protein analytes were captured from serum in a capture chamber by 1-μm magnetic beads coated with antibodies and enzyme labels. Beads are then transported downstream to a detection chamber containing an eight-sensor array coated with glutathione-coated gold nanoparticles (GSH-AuNP) and a second set of antibodies to capture the beads with analyte proteins. In this first application of the immunoarray to four-protein multiplexed measurements, ultralow detection limits of 10–40 fg mL−1 in 5 μL serum were achieved for simultaneous detection in 30 min. Mass detection limits were 2.5–10 zmol, as few as 1500 molecules. Accuracy and diagnostic utility of the arrays were demonstrated by correlation of levels of the four biomarker proteins in serum from head and neck cancer patients with results from standard ELISA. This approach may lead to rapid, low-cost estimates of projected risk for severity of oral mucositis in cancer patients to enable improved therapeutic management.
- 5 July 2015
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 407 (23) , 7239-7243
Ultrasensitive microfluidic array for serum pro-inflammatory cytokines and C-reactive protein to assess oral mucositis risk in cancer patients
In addition to disease diagnostics, there is a need for biomarkers to predict severity of cancer therapy side effects such as oral mucositis. Oral mucositis is an inflammatory lesion of oral mucosa caused by high-dose chemotherapy and/or radiation that is especially prevalent during oral cancer treatment. We describe here a semi-automated, modular microfluidic immunoarray optimized for ultrasensitive detection of pro-inflammatory cytokines involved in pathobiology of oral mucositis. Our goal is to methodologically identify risk of mucositis early in oral cancer treatment, before the onset of lesions. Biomarkers include tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), and C-reactive protein (CRP). Protein analytes were captured from serum in a capture chamber by 1-μm magnetic beads coated with antibodies and enzyme labels. Beads are then transported downstream to a detection chamber containing an eight-sensor array coated with glutathione-coated gold nanoparticles (GSH-AuNP) and a second set of antibodies to capture the beads with analyte proteins. In this first application of the immunoarray to four-protein multiplexed measurements, ultralow detection limits of 10–40 fg mL−1 in 5 μL serum were achieved for simultaneous detection in 30 min. Mass detection limits were 2.5–10 zmol, as few as 1500 molecules. Accuracy and diagnostic utility of the arrays were demonstrated by correlation of levels of the four biomarker proteins in serum from head and neck cancer patients with results from standard ELISA. This approach may lead to rapid, low-cost estimates of projected risk for severity of oral mucositis in cancer patients to enable improved therapeutic management.
- 14 April 2014
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 6 (13) , 4602-4609
Matrix-assisted laser desorption/ionization mass spectrometry analysis of dimethyl arginine isomers from urine
Isomeric asymmetric and symmetric dimethyl arginine (ADMA and SDMA respectively) residues are excreted in urine and are putative markers of cardiovascular and chronic kidney diseases. In this work, we demonstrate simultaneous and quantitative detection of endogeneous ADMA and SDMA from urine samples of healthy subjects using MALDI-TOF MS without any chromatographic separation. The DMA isomers yielded [M + H]+ ions along with their product ions formed due to MALDI in-source fragmentation. The precursor ions were validated using MALDI-TOF MS/MS as well as direct injection ESI-Q-TOF MS/MS. ADMA and SDMA generated unique product ions at ∼ m/z 46 and ∼ m/z 172 respectively in the MS-mode itself. These were advantageously used for full scan-mode absolute quantification of the isomeric metabolites. The m/z observed for all the ions was within 10 ppm mass accuracy. The calibration method was established by generating internal standard normalized peak area-based concentration response curves using synthetic standards. Good linearities (R2 > 0.95) with acceptable intra-assay, inter-assay variation (within 15% RSD) and excellent recoveries were observed for quality control samples. Finally, endogeneous concentrations of the metabolites were determined in urine from healthy subjects (n = 11). ADMA and SDMA were found to be in the range of 1.6–8 μM and 2.9–9.1 μM in urine and were in agreement with previously reported physiological levels.
- 14 April 2014
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 6 (13) , 4602-4609
Matrix-assisted laser desorption/ionization mass spectrometry analysis of dimethyl arginine isomers from urine
Isomeric asymmetric and symmetric dimethyl arginine (ADMA and SDMA respectively) residues are excreted in urine and are putative markers of cardiovascular and chronic kidney diseases. In this work, we demonstrate simultaneous and quantitative detection of endogeneous ADMA and SDMA from urine samples of healthy subjects using MALDI-TOF MS without any chromatographic separation. The DMA isomers yielded [M + H]+ ions along with their product ions formed due to MALDI in-source fragmentation. The precursor ions were validated using MALDI-TOF MS/MS as well as direct injection ESI-Q-TOF MS/MS. ADMA and SDMA generated unique product ions at ∼ m/z 46 and ∼ m/z 172 respectively in the MS-mode itself. These were advantageously used for full scan-mode absolute quantification of the isomeric metabolites. The m/z observed for all the ions was within 10 ppm mass accuracy. The calibration method was established by generating internal standard normalized peak area-based concentration response curves using synthetic standards. Good linearities (R2 > 0.95) with acceptable intra-assay, inter-assay variation (within 15% RSD) and excellent recoveries were observed for quality control samples. Finally, endogeneous concentrations of the metabolites were determined in urine from healthy subjects (n = 11). ADMA and SDMA were found to be in the range of 1.6–8 μM and 2.9–9.1 μM in urine and were in agreement with previously reported physiological levels.